Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 5,915 shares, a drop of 82.9% from the August 31st total of 34,593 shares. Based on an average daily volume of 38,250 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.4% of the shares of the stock are sold short.

Institutional Trading of Global X Genomics & Biotechnology ETF

An institutional investor recently raised its stake in Global X Genomics & Biotechnology ETF stock. Bank of America Corp DE raised its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 67.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 119,795 shares of the company’s stock after purchasing an additional 48,394 shares during the period. Bank of America Corp DE owned 10.70% of Global X Genomics & Biotechnology ETF worth $5,240,000 at the end of the most recent reporting period. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM traded down $0.08 during midday trading on Friday, hitting $70.17. 76,480 shares of the company traded hands, compared to its average volume of 18,609. The stock has a 50-day moving average of $61.52 and a 200-day moving average of $52.90. Global X Genomics & Biotechnology ETF has a one year low of $37.25 and a one year high of $70.83. The firm has a market cap of $105.25 million, a P/E ratio of -29.99 and a beta of 1.19.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.